Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

<p>Merestinib and LY2874455 inhibit MET-activated signal transduction. A, AML cell lines treated with merestinib and LY2874455 in vitro for 1 hour exhibited decreased levels of pSTAT3 and pSTAT5 by phospho-flow cytometry. Standard errors are shown for KG1a (n=3) and HEL (n=2) cell lines. Repre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Evan C. Chen (15054014) (author)
Otros Autores: Helen Gandler (15054017) (author), Isidora Tošić (15054020) (author), Geoffrey G. Fell (15054023) (author), Ashlee Fiore (15054026) (author), Olga Pozdnyakova (15054029) (author), Daniel J. DeAngelo (15031959) (author), Ilene Galinsky (15054032) (author), Marlise R. Luskin (15054035) (author), Martha Wadleigh (15054038) (author), Eric S. Winer (15054041) (author), Rebecca Leonard (15054044) (author), Kelsey O'Day (15054047) (author), Adrienne de Jonge (15054050) (author), Donna Neuberg (15038318) (author), A. Thomas Look (14951403) (author), Richard M. Stone (15054053) (author), David A. Frank (14961075) (author), Jacqueline S. Garcia (15043140) (author)
Publicado: 2025
Materias:
Cancer
Therapeutic Research and Development
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Drug Targets
Protein kinase & phosphatase drug targets
Hematological Cancers
Leukemias
Pharmacology
Pharmacokinetics and pharmacodynamics
Precision Medicine
Small Molecule Agents
Kinase inhibitors
Translational Research
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Sea el primero en dejar un comentario!
Primero debe ingresar al sistema

Ejemplares similares